P/E ratio for MacroGenics (MGNX)
P/E ratio as of June 2024 (TTM): 32.6
According to MacroGenics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 32.6154. At the end of 2022 the company had a P/E ratio of -3.46.
P/E ratio history for MacroGenics from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.46 | -27.38% |
| 2021 | -4.76 | -48.12% |
| 2020 | -9.18 | 167.49% |
| 2019 | -3.43 | 14.59% |
| 2018 | -3.00 | -91.49% |
| 2017 | -35.2 | 189.19% |
| 2016 | -12.2 | -78.79% |
| 2015 | -57.4 | 127.31% |
| 2014 | -25.2 | -95.02% |
| 2013 | -507 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 15.2 | -53.51% | 🇺🇸 USA |
 Eli Lilly LLY | 150 | 360.28% | 🇺🇸 USA |
 Amgen AMGN | 21.3 | -34.78% | 🇺🇸 USA |
 Gilead Sciences GILD | 14.6 | -55.25% | 🇺🇸 USA |
 Merck MRK | 68.4 | 109.59% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 10.1 | -68.91% | 🇺🇸 USA |
 Xencor XNCR | -11.2 | -134.23% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.